Stem cell therapy for macular degeneration
.jpg)
Stem cell therapy for macular degeneration is an emerging treatment approach aimed at restoring vision in individuals suffering from various forms of macular degeneration, particularly age-related macular degeneration (AMD).[1] This therapy involves the transplantation of stem cells into the retina to replace damaged or lost retinal pigment epithelium (RPE) and photoreceptor cells, which are critical for central vision. Clinical trials have shown promise in stabilizing or improving visual function, but are nevertheless inefficient.[2]
History
[edit]The first fetal retinal transplant into the anterior chamber of animal eyes was reported in 1959. In 1980, experiments involving cell cultures of retinal pigment epithelium (RPE) began. Human RPE cells grown in culture were subsequently transplanted into animal eyes, initially using open techniques and later through closed cavity vitrectomy methods.[1]
In 1991, Gholam Peyman attempted to transplant RPE in humans, but the success rate was limited. Later efforts focused on allogenic fetal RPE cell transplantation, which faced significant challenges due to immune rejection. It was observed that rejection rates were lower in cases of dry age-related macular degeneration (AMD) compared to the wet form of the disease. Autologous RPE transplantation became more common, using two main techniques: RPE suspension and full-thickness RPE-choroid transplantation. Clinical outcomes from autologous RPE-choroid transplantation, where tissue from the eye’s periphery is transplanted to a diseased area, have shown promise.[3]
Since 2003, researchers have successfully transplanted corneal stem cells into damaged eyes to restore vision. Sheets of retinal cells used in these procedures were initially harvested from aborted fetuses, which raised ethical concerns for some. These retinal sheets, when transplanted over damaged corneas, stimulated repair and eventually restored vision.[4][5] In June 2005, a team led by Sheraz Daya at Queen Victoria Hospital in Sussex, England, restored sight in forty patients using a similar technique with adult stem cells sourced from the patient, a relative, or a cadaver.[6]
In 2014, surgeons at Riken Institute’s Center for Developmental Biology reported the first transplantation of induced pluripotent stem cells (iPSCs) into a human patient. This clinical study involved creating a retinal sheet from iPSCs, developed by Shinya Yamanaka, which were reprogrammed from the patient's own mature cells. The retinal sheet was transplanted into a woman in her 70s suffering from age-related macular degeneration (AMD), a condition that blurs central vision and can lead to blindness. The use of iPSCs aimed to halt the progression of AMD. In March 2017, the team conducted the first successful transplant of retinal cells created from donor-derived iPSCs into a patient with advanced wet AMD. This surgery was made more efficient by using "super donor" cells, derived from individuals with specific white blood cell types that reduce the risk of immune rejection. Approximately 250,000 retinal pigment epithelial cells, generated from these donor-derived iPSCs, were transplanted into the patient’s eye.[7]
See also
[edit]- Cell therapy
- Ophthalmology
- Stem cell therapy
- Macular degeneration
- Gene therapy for color blindness
- Gene therapy of the human retina
References
[edit]- ^ a b John S, Natarajan S, Parikumar P, Shanmugam PM, Senthilkumar R, Green DW, et al. (2013). "Choice of Cell Source in Cell-Based Therapies for Retinal Damage due to Age-Related Macular Degeneration: A Review". Journal of Ophthalmology. 2013: 465169. doi:10.1155/2013/465169. PMC 3654320. PMID 23710332.
- ^ O'Neill HC, Limnios IJ, Barnett NL (2020). "Advancing a Stem Cell Therapy for Age-Related Macular Degeneration". Current Stem Cell Research & Therapy. 15 (2): 89–97. doi:10.2174/1574888X15666191218094020. PMID 31854278.
- ^ Chen FK, Uppal GS, MacLaren RE, Coffey PJ, Rubin GS, Tufail A, et al. (April 2009). "Long-term visual and microperimetry outcomes following autologous retinal pigment epithelium choroid graft for neovascular age-related macular degeneration". Clinical & Experimental Ophthalmology. 37 (3): 275–85. doi:10.1111/j.1442-9071.2009.01915.x. PMID 19459869.
- ^ "Fetal tissue restores lost sight". MedicalNewsToday. 28 October 2004. Archived from the original on 19 May 2006.
- ^ Seiler MJ, Aramant RB (November 2012). "Cell replacement and visual restoration by retinal sheet transplants". Progress in Retinal and Eye Research. 31 (6): 661–87. doi:10.1016/j.preteyeres.2012.06.003. PMC 3472113. PMID 22771454.
- ^ "Stem cells used to restore vision". 28 April 2005 – via news.bbc.co.uk.
- ^ Mandai M, Watanabe A, Kurimoto Y, Hirami Y, Morinaga C, Daimon T, et al. (March 2017). "Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration". The New England Journal of Medicine. 376 (11): 1038–1046. doi:10.1056/nejmoa1608368. PMID 28296613. S2CID 27993960.
Further reading
[edit]- Atala A (February 2012). "Human embryonic stem cells: early hints on safety and efficacy". Lancet. 379 (9817): 689–690. doi:10.1016/S0140-6736(12)60118-4. PMID 22281387.
- Bharti K, Rao M, Hull SC, Stroncek D, Brooks BP, Feigal E, et al. (February 2014). "Developing cellular therapies for retinal degenerative diseases". Investigative Ophthalmology & Visual Science. 55 (2): 1191–1202. doi:10.1167/iovs.13-13481. PMC 4587754. PMID 24573369.
- Bhutto I, Lutty G (August 2012). "Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex". Molecular Aspects of Medicine. 33 (4): 295–317. doi:10.1016/j.mam.2012.04.005. PMC 3392421. PMID 22542780.
- Haruta, M. et al. In vitro and in vivo characterization of pigment epithelial cells differentiated from primate embryonic stem cells. Invest. Ophthalmol. Vis. Sci. 45, 1020–1025 (2004).
- Muthiah MN, Keane PA, Zhong J, Gias C, Uppal G, Coffey PJ, et al. (January 2014). "Adaptive optics imaging shows rescue of macula cone photoreceptors". Ophthalmology. 121 (1): 430–431.e3. doi:10.1016/j.ophtha.2013.10.008. PMID 24268491.
- Nazari H, Zhang L, Zhu D, Chader GJ, Falabella P, Stefanini F, et al. (September 2015). "Stem cell based therapies for age-related macular degeneration: The promises and the challenges". Progress in Retinal and Eye Research. 48: 1–39. doi:10.1016/j.preteyeres.2015.06.004. PMID 26113213.
- Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. (October 2006). "Ranibizumab for neovascular age-related macular degeneration". The New England Journal of Medicine. 355 (14): 1419–31. doi:10.1056/NEJMoa054481. PMID 17021318.
- Schwartz SD, Regillo CD, Lam BL, Eliott D, Rosenfeld PJ, Gregori NZ, et al. (February 2015). "Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies". Lancet (London, England). 385 (9967): 509–16. doi:10.1016/S0140-6736(14)61376-3. PMID 25458728.
- Vugler A, Carr AJ, Lawrence J, Chen LL, Burrell K, Wright A, et al. (December 2008). "Elucidating the phenomenon of HESC-derived RPE: anatomy of cell genesis, expansion and retinal transplantation". Experimental Neurology. 214 (2): 347–61. doi:10.1016/j.expneurol.2008.09.007. PMID 18926821.